PL433567A1 - Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych - Google Patents

Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych

Info

Publication number
PL433567A1
PL433567A1 PL433567A PL43356720A PL433567A1 PL 433567 A1 PL433567 A1 PL 433567A1 PL 433567 A PL433567 A PL 433567A PL 43356720 A PL43356720 A PL 43356720A PL 433567 A1 PL433567 A1 PL 433567A1
Authority
PL
Poland
Prior art keywords
treatment
amino acid
water
acid derivatives
modified amino
Prior art date
Application number
PL433567A
Other languages
English (en)
Other versions
PL243119B1 (pl
Inventor
Krzysztof KAMIŃSKI
Michał ABRAM
Marcin JAKUBIEC
Anna RAPACZ
Szczepan MOGILSKI
Gniewomir LATACZ
Marta STRUGA
Original Assignee
Uniwersytet Jagielloński
Warszawski Uniwersytet Medyczny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Jagielloński, Warszawski Uniwersytet Medyczny filed Critical Uniwersytet Jagielloński
Priority to PL433567A priority Critical patent/PL243119B1/pl
Priority to CA3175613A priority patent/CA3175613A1/en
Priority to EP24215754.3A priority patent/EP4527384A3/en
Priority to CN202180038326.1A priority patent/CN115715219B/zh
Priority to ES21732998T priority patent/ES3020435T3/es
Priority to PCT/PL2021/050026 priority patent/WO2021210997A1/en
Priority to US17/996,235 priority patent/US20230192608A1/en
Priority to EP21732998.6A priority patent/EP4135840B1/en
Priority to PL21732998.6T priority patent/PL4135840T3/pl
Publication of PL433567A1 publication Critical patent/PL433567A1/pl
Publication of PL243119B1 publication Critical patent/PL243119B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Przedmiotem zgłoszenia jest związek o wzorze (I): gdzie X oznacza wodór lub N(CH3)2, Y oznacza CH2 lub C=O, R oznacza wodór lub atom fluorowca, korzystnie F, przy czym gdy Y oznacza C=O to X oznacza N(CH3)2, lub jego izomery optyczne, ich mieszaniny oraz farmaceutycznie dopuszczalne sole.
PL433567A 2020-04-16 2020-04-16 Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe nadające się do leczenia chorób o podłożu neurologicznym oraz zaburzeń psychiatrycznych PL243119B1 (pl)

Priority Applications (9)

Application Number Priority Date Filing Date Title
PL433567A PL243119B1 (pl) 2020-04-16 2020-04-16 Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe nadające się do leczenia chorób o podłożu neurologicznym oraz zaburzeń psychiatrycznych
CA3175613A CA3175613A1 (en) 2020-04-16 2021-04-16 Water-soluble, modified amino acid derivatives for treatment of neurological diseases, and selected psychiatric disorders
EP24215754.3A EP4527384A3 (en) 2020-04-16 2021-04-16 Water-soluble, modified amino acid derivatives for the treatment of neurological diseases and selected psychiatric disorders
CN202180038326.1A CN115715219B (zh) 2020-04-16 2021-04-16 用于治疗神经系统疾病和选择的精神疾患的水溶性、修饰的氨基酸衍生物
ES21732998T ES3020435T3 (en) 2020-04-16 2021-04-16 Water-soluble, modified amino acid derivatives for the treatment of neurological diseases and selected psychiatric disorders
PCT/PL2021/050026 WO2021210997A1 (en) 2020-04-16 2021-04-16 Water-soluble, modified amino acid derivatives for treatment of neurological diseases, and selected psychiatric disorders
US17/996,235 US20230192608A1 (en) 2020-04-16 2021-04-16 Water-soluble, modified amino acid derivatives for treatment of neurological diseases, and selected psychiatric disorders
EP21732998.6A EP4135840B1 (en) 2020-04-16 2021-04-16 Water-soluble, modified amino acid derivatives for the treatment of neurological diseases and selected psychiatric disorders
PL21732998.6T PL4135840T3 (pl) 2020-04-16 2021-04-16 Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL433567A PL243119B1 (pl) 2020-04-16 2020-04-16 Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe nadające się do leczenia chorób o podłożu neurologicznym oraz zaburzeń psychiatrycznych

Publications (2)

Publication Number Publication Date
PL433567A1 true PL433567A1 (pl) 2021-10-18
PL243119B1 PL243119B1 (pl) 2023-06-26

Family

ID=76483335

Family Applications (2)

Application Number Title Priority Date Filing Date
PL433567A PL243119B1 (pl) 2020-04-16 2020-04-16 Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe nadające się do leczenia chorób o podłożu neurologicznym oraz zaburzeń psychiatrycznych
PL21732998.6T PL4135840T3 (pl) 2020-04-16 2021-04-16 Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL21732998.6T PL4135840T3 (pl) 2020-04-16 2021-04-16 Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych

Country Status (7)

Country Link
US (1) US20230192608A1 (pl)
EP (2) EP4527384A3 (pl)
CN (1) CN115715219B (pl)
CA (1) CA3175613A1 (pl)
ES (1) ES3020435T3 (pl)
PL (2) PL243119B1 (pl)
WO (1) WO2021210997A1 (pl)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL450241A1 (pl) * 2024-11-12 2026-05-18 Uniwersytet Jagielloński Pozytywny allosteryczny modulator (PAM) transportera EAAT2/GLT-1 glutaminianu do stosowania w leczeniu lub zapobieganiu świądu

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL240297B1 (pl) 2019-04-16 2022-03-14 Univ Jagiellonski Modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych
WO2026150001A1 (en) 2025-01-09 2026-07-16 Iqure Pharma Inc. Positive allosteric modulator (pam) of the eaat2/glt-1 glutamate transporter for use in the treatment or prevention of dravet syndrome

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW288010B (pl) * 1992-03-05 1996-10-11 Pfizer
PL240297B1 (pl) 2019-04-16 2022-03-14 Univ Jagiellonski Modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL450241A1 (pl) * 2024-11-12 2026-05-18 Uniwersytet Jagielloński Pozytywny allosteryczny modulator (PAM) transportera EAAT2/GLT-1 glutaminianu do stosowania w leczeniu lub zapobieganiu świądu

Also Published As

Publication number Publication date
CN115715219B (zh) 2026-01-06
PL4135840T3 (pl) 2025-05-12
PL243119B1 (pl) 2023-06-26
EP4527384A3 (en) 2025-07-02
EP4135840A1 (en) 2023-02-22
US20230192608A1 (en) 2023-06-22
WO2021210997A1 (en) 2021-10-21
CN115715219A (zh) 2023-02-24
ES3020435T3 (en) 2025-05-22
EP4135840B1 (en) 2025-01-08
CA3175613A1 (en) 2021-10-21
EP4527384A2 (en) 2025-03-26

Similar Documents

Publication Publication Date Title
MX2022010795A (es) Hidrato cristalino de un compuesto inhibidor de jak.
CL2025002925A1 (es) Compuestos derivados de pirido[4,3–d]pirimidina y uso para tratar cáncer.
BR112022008919A2 (pt) Composto e método para tratamento de distúrbios psiquiátrico ou neurológico
MXPA04009784A (es) Tiazolidin-4-carbonitrilos y analogos y su uso como inhibidores de dipeptidil-peptidas.
SA523451700B1 (ar) (pi3k) مثبطات الكرومينون الألستيرية للفوسفونوسيتيد 3-كيناز لعلاج السرطان
EA200000188A1 (ru) Производные 2,3-диарил-пиразоло[1,5-b]-пиридазинов, их получение и их применение в качестве ингибиторов циклооксигеназы-2 (цог-2)
CY1109490T1 (el) Τρικυκλικοι τροποποιητες πυρηνικων υποδοχεων στεροειδων ορμονων
SE0104334D0 (sv) Therapeutic agents
SE0202462D0 (sv) Novel use
CA2485685A1 (en) Calcium receptor modulating agents
HRP20080175T3 (hr) Supstituirani 2-aminotetrtalini, namijenjeni preventivnom liječenju parkinsonove bolesti
WO2020247298A3 (en) 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
EA202192900A1 (ru) Модуляторы пути интегрированной реакции на стресс
MX2024003459A (es) Metodos de tratamiento de trastornos metabolicos.
PL432858A1 (pl) Związki stanowiące C20-modyfikowane pochodne salinomycyny, sposób ich otrzymywania, kompozycja je zawierająca, zastosowanie tych związków oraz sposób otrzymywania produktu pośredniego
ZA202306437B (en) Salt and crystal form of nitrogen-containing heterocyclic derivative, preparation method therefor and application thereof
WO2024097172A9 (en) Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
JOP20250101A1 (ar) مشتقات بنز إيميدازول حلقية كمثبطات cGAS
DK1390036T3 (da) Prostansyrederivater som midler til nedsættelse af intraokulært tryk
BRPI0417844A (pt) derivados de amida contendo um substituinte de ciclopropilaminocarbonila, de utilidade como inibidores de citocina
ZA202203360B (en) Peptide amide composition and preparation method therefor
PT871626E (pt) Triazolonas utilizadas como inibidores de sintese da apoliproteina b
NO20023041L (no) Fremgangsmåte for fremstilling av pyrazolopyridazinderivater
RU2008109821A (ru) Способ и композиция для стимуляции нейрогенеза и ингибирования дегенерации нейронов
PE20251590A1 (es) Nuevos derivados pirazina-carboxamida sustituidos